» Authors » Sandra Sauer

Sandra Sauer

Explore the profile of Sandra Sauer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 52
Citations 306
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Lutz R, Poos A, Sole-Boldo L, John L, Wagner J, Prokoph N, et al.
Sci Immunol . 2025 Feb; 10(104):eadp6667. PMID: 39919199
The bone marrow microenvironment plays a crucial role in the development of multiple myeloma. As the disease progresses, malignant myeloma cells can evolve to survive outside the bone marrow. However,...
2.
Bauer F, Kachele J, Bernhard J, Hajiyianni M, Weinhold N, Sauer S, et al.
Acad Radiol . 2025 Jan; PMID: 39848889
Rationale And Objectives: To establish an advanced automated bone marrow (BM) segmentation model on whole-body (WB-)MRI in monoclonal plasma cell disorders (MPCD), and to demonstrate its robust performance on multicenter...
3.
Baertsch M, Schlenzka J, Hielscher T, Raab M, Sauer S, Merz M, et al.
Blood . 2025 Jan; PMID: 39808798
The multicenter, phase III GMMG ReLApsE trial (EudraCT-No:2009-013856-61) randomized relapsed and/or refractory multiple myeloma (RRMM) patients equally to lenalidomide/dexamethasone (LEN/DEX, 25mg days 1-21/40mg weekly, 4-week cycles) re-induction, salvage high dose...
4.
Grieb N, Oeser A, Ferle M, Hanke F, Flossdorf S, Sauer S, et al.
Bone Marrow Transplant . 2024 Dec; 60(3):335-345. PMID: 39638882
Identifying patients who may benefit from autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma is crucial, especially in the era of effective induction and consolidation strategies. We analyzed...
5.
Neelsen C, Sachpekidis C, John L, Neher P, Mai E, Grozinger M, et al.
Eur Radiol . 2024 Nov; PMID: 39604650
Objectives: This study aims to evaluate correlations between spleen signal changes in different MRI sequences and bone marrow plasma cell infiltration as potential indicator of disease burden in multiple myeloma...
6.
Frenking J, Zhou X, Wagner V, Hielscher T, Kauer J, Mai E, et al.
J Immunother Cancer . 2024 Oct; 12(10). PMID: 39379098
Background: Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant benefits in the treatment of relapsed/refractory multiple myeloma (RRMM). However, these outcomes can be compromised by severe complications, including cytokine...
7.
Klein E, Hujic S, Miah K, Benner A, Merz M, Bertsch U, et al.
Oncology . 2024 Oct; :1-11. PMID: 39362191
Introduction: Although recent data suggest that melphalan high-dose therapy followed by autologous stem cell transplantation (HDT/ASCT) is safe and effective in eligible multiple myeloma (MM) patients up to the age...
8.
Zuern K, Hielscher T, Werly A, Breitkreutz I, Sauer S, Raab M, et al.
Blood Cancer J . 2024 Aug; 14(1):148. PMID: 39191769
Risk of progression of monoclonal gammopathy of undetermined significance (MGUS) into multiple myeloma and related plasma cell disorders can be determined by three major risk stratification models, namely Mayo2005, Sweden2014,...
9.
Janssen M, Leo A, Wolf C, Stenzinger M, Bartenschlager M, Brandt J, et al.
Int J Cancer . 2024 May; 155(4):618-626. PMID: 38721724
Immunocompromised patients are at high risk to fail clearance of SARS-CoV-2. Prolonged COVID-19 constitutes a health risk and a management problem as cancer treatments often have to be disrupted. As...
10.
Sauer S, Engelhardt M, Trautmann-Grill K, Kimmich C, Hanel M, Schmidt-Hieber M, et al.
Bone Marrow Transplant . 2024 Mar; 59(6):880-889. PMID: 38480852
There are limited data guiding choice of re-induction therapies for patients with relapsed/refractory multiple myeloma (RRMM) prior to stem cell transplantation (SCT). We performed a retrospective medical chart review of...